AKT1 and acute myeloid leukemia: Treatment with BMS-536924, a small molecule IGF-1R/insulin-receptor kinase inhibitor, reduced proliferation and induced apoptosis among AML cells through inhibition of downstream MEK1/2 and Akt signaling [192,193].